Assembly Biosciences, Inc. (Assembly) is a biopharmaceutical company. The Company is engaged in the development of oral therapies for the cure of intractable infectious diseases, focusing on hepatitis B virus (HBV) and clostridium (C.) difficile-associated infections (CDAD). The target of Assembly’s lead program is a clinical cure for HBV, for, which it is developing a series of compounds, known as core protein allosteric modulators (CpAMs). Assembly’s clinical strategy includes testing CpAMs as monotherapy and in combination. Assembly’s CDAD program is -based on the targeted delivery of microbiome-based therapies in an oral formulation, applying Assembly’s coating and encapsulation technology that allows for targeted delivery of complex agents to select regions of the gastrointestinal (GI) tract. The Company’s HBV and microbiome therapies are both in pre-clinical development stages.
